BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kapadia MK, Rubin PAD. The Emerging Use of TNF-?? Inhibitors in Orbital Inflammatory Disease: . International Ophthalmology Clinics 2006;46:165-81. [DOI: 10.1097/00004397-200604620-00014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Smith TJ. Pathogenesis of Graves' orbitopathy: a 2010 update. J Endocrinol Invest 2010;33:414-21. [PMID: 20631493 DOI: 10.1007/BF03346614] [Cited by in Crossref: 54] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
2 Kim DH, Kim HS. Recurrent orbital myositis in undifferentiated connective tissue disease. Joint Bone Spine 2013;80:110-1. [PMID: 22840478 DOI: 10.1016/j.jbspin.2012.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
3 Zhang Y, Li X, Guo C, Dong J, Liao L. Mechanisms of Spica Prunellae against thyroid-associated Ophthalmopathy based on network pharmacology and molecular docking. BMC Complement Med Ther 2020;20:229. [PMID: 32689994 DOI: 10.1186/s12906-020-03022-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Lee MJ, Planck SR, Choi D, Harrington CA, Wilson DJ, Dailey RA, Ng JD, Steele EA, Hamilton BE, Khwarg SI, Rosenbaum JT. Non-specific orbital inflammation: Current understanding and unmet needs. Prog Retin Eye Res 2021;81:100885. [PMID: 32717379 DOI: 10.1016/j.preteyeres.2020.100885] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 He Q, Dong H, Gong M, Guo Y, Xia Q, Gong J, Lu F. New Therapeutic Horizon of Graves' Hyperthyroidism: Treatment Regimens Based on Immunology and Ingredients From Traditional Chinese Medicine. Front Pharmacol 2022;13:862831. [PMID: 35462920 DOI: 10.3389/fphar.2022.862831] [Reference Citation Analysis]
6 Kurt G, Ergün E, Cemil B, Börcek AO, Börcek P, Gülbahar O, Ceviker N. Neuroprotective effects of infliximab in experimental spinal cord injury. Surg Neurol. 2009;71:332-336, discussion 336. [PMID: 18440605 DOI: 10.1016/j.surneu.2008.01.038] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
7 Idowu OO, Saifee M, Copperman TS, Kersten RC. Dacryoadenitis Associated With Juvenile Idiopathic Arthritis. Ophthalmic Plast Reconstr Surg 2020;36:e63-5. [PMID: 31880684 DOI: 10.1097/IOP.0000000000001573] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Lutt JR, Lim LL, Phal PM, Rosenbaum JT. Orbital Inflammatory Disease. Seminars in Arthritis and Rheumatism 2008;37:207-22. [DOI: 10.1016/j.semarthrit.2007.06.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 51] [Article Influence: 5.6] [Reference Citation Analysis]
9 van der Woerdt A. Orbital inflammatory disease and pseudotumor in dogs and cats. Vet Clin North Am Small Anim Pract 2008;38:389-401, vii-viii. [PMID: 18299013 DOI: 10.1016/j.cvsm.2007.11.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
10 Escudero González CM, Rodríguez Montero S, Martínez Pérez R, Pastor Mañosa C, Velloso Feijoo ML, Marenco de la Fuente JL. [Resistant orbital pseudotumor treated with rituximab in a patient with systemic lupus erythematosus. A case presentation]. Reumatol Clin 2010;6:214-6. [PMID: 21794716 DOI: 10.1016/j.reuma.2009.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Díaz-Torné C, Narváez J, De Lama E, Diez-García M, Narváez JA, Bernad B, Llatjos R, Nolla JM, Valverde J. Inflammatory pseudotumor of the liver associated with rheumatoid arthritis. Arthritis Rheum 2007;57:1102-6. [PMID: 17665472 DOI: 10.1002/art.22904] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
12 Pakdel F, Haghighi A, Pirmarzdashti N. Disease modifying drugs in idiopathic sclerosing orbital inflammatory syndrome. Orbit 2021;:1-10. [PMID: 34030586 DOI: 10.1080/01676830.2021.1929338] [Reference Citation Analysis]
13 Xu MN, Pan ZQ, Tu YH, Tao HQ, Shi KS, Wu WC. Therapeutic difference between orbital decompression and glucocorticoids administration as the first-line treatment for dysthyroid optic neuropathy: a systematic review. Int J Ophthalmol 2021;14:1107-13. [PMID: 34282398 DOI: 10.18240/ijo.2021.07.21] [Reference Citation Analysis]
14 Miyawaki EK, Hsu L, Bhattacharyya S, O'Hare MJ, Roy A, Kett L, Caplan RA, Dattilo LW, Jo VY, Guenette JP. Fibrosing Inflammatory Pseudotumor Presenting as Cranial Neuropathy. Case Rep Neurol 2020;12:247-54. [PMID: 32774282 DOI: 10.1159/000507920] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Schellini SA, Marques-fernandez V, Meneghim RLFS, Galindo-ferreiro A. Current management strategies of congenital nasolacrimal duct obstructions. Expert Review of Ophthalmology 2021;16:377-85. [DOI: 10.1080/17469899.2021.1945923] [Reference Citation Analysis]